| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/06/2005 | CN1604904A Phosphonic acid compounds as inhibitors of serine proteases |
| 04/06/2005 | CN1604901A Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/06/2005 | CN1604900A 6-aminomorphinane derivatives, method for production and use thereof |
| 04/06/2005 | CN1604898A 3-heteroaryl-3, 5-dihydro-4-oxo-4h-pyridazino[4, 5-b]indole-1-carboxamide derivatives, their preparation, their intermediates and pharmaceutical compositions containing the compounds |
| 04/06/2005 | CN1604897A 7-amino-benzothiazole derivatives as adenosine receptor ligands |
| 04/06/2005 | CN1604893A Cyclic amine compounds |
| 04/06/2005 | CN1604795A Combination motif immune stimulatory oligonucleotides with improved activity |
| 04/06/2005 | CN1604792A Agents for enhancing the immune response |
| 04/06/2005 | CN1604776A 4-4-alkoxy-3-hydroxyphenyl-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/06/2005 | CN1603342A Caspase-8 interacting proteins |
| 04/06/2005 | CN1603291A Novel intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 04/06/2005 | CN1602956A Deactivated BCG for treating disease |
| 04/06/2005 | CN1602890A Preparation for brown algae amylose complexing agent capable of improving chlamys farreri immunity and feeding method thereof |
| 04/06/2005 | CN1602886A Pharmaceutical compositions and its application |
| 04/06/2005 | CN1602868A Dripping pills of ketotifen fumarate and its preparation method |
| 04/06/2005 | CN1602866A Dripping pills of tripelennamine hydrochloride and its preparation method |
| 04/06/2005 | CN1602860A Dripping pills of clemastine fumarate and its preparation method |
| 04/06/2005 | CN1602857A Orally disintegrating tablet of safflor yellow and its preparation process |
| 04/06/2005 | CN1602841A Immuno-modulatory agents administration form for whole body or local immunity disorder |
| 04/06/2005 | CN1195860C Delivery of biologically active polypeptides |
| 04/06/2005 | CN1195853C Neurotrophic factor NNT-1 |
| 04/06/2005 | CN1195778C Cell adhension inhibitors |
| 04/06/2005 | CN1195755C Pyrrolo [2, 3-d] pyrimidine compounds |
| 04/06/2005 | CN1195546C Application of monoclone antibody combined with CD154 for inhibiting rejection of insulin generating transplanted tissue |
| 04/06/2005 | CN1195529C Composition containing muscle-derived active agents |
| 04/06/2005 | CN1195526C Medicinal products containing antimer pure beta-D-dioxypentacyclic nucleoside |
| 04/06/2005 | CN1195513C Tocopherols, tocotrienols, other chroman and side chain derivatives and uses |
| 04/06/2005 | CN1195511C The use of fumaric acid derivatives in transplant medicine |
| 04/06/2005 | CN1195495C Emulsion preconcentrate containing cyclosporin or macrolide |
| 04/05/2005 | US6875868 Pteridine compounds for the treatment of psoriasis |
| 04/05/2005 | US6875848 Process for the production of virus-inactivated human gammaglobulin G |
| 04/05/2005 | US6875846 Heterologous polypeptide of the TNF family |
| 04/05/2005 | US6875789 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875777 Compounds |
| 04/05/2005 | US6875762 Tetracyclic azepinoindole compounds |
| 04/05/2005 | US6875737 Multivalent compounds for crosslinking receptors and uses thereof |
| 04/05/2005 | US6875736 Methods for identifying RNA binding compounds |
| 04/05/2005 | US6875612 Expression vector coding proteins for use in the treatment of tumors |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 04/05/2005 | US6875435 In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
| 04/05/2005 | US6875430 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 04/05/2005 | US6875422 Oral treatment/care agent |
| 04/05/2005 | CA1341478C Therapeutic methods using catalytic antibodies |
| 03/31/2005 | WO2005028514A1 Use of a compound for reducing the biological effectiveness of il-6 |
| 03/31/2005 | WO2005028513A2 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine |
| 03/31/2005 | WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 03/31/2005 | WO2005028454A1 Haloalkyl containing compounds as cysteine protease inhibitors |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005027966A2 Antibodies with altered effector functions |
| 03/31/2005 | WO2005027965A1 Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| 03/31/2005 | WO2005027958A1 Thymosin-beta-sulphoxide as an immunosuppressive active agent |
| 03/31/2005 | WO2005027956A1 Method of treating allergy and/or airway disease |
| 03/31/2005 | WO2005027952A1 Composition exerting physiological activity via biological immune mechanism |
| 03/31/2005 | WO2005027941A1 Skin preparation for external use |
| 03/31/2005 | WO2005027936A2 Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans |
| 03/31/2005 | WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER |
| 03/31/2005 | WO2005027831A2 Modulators of p-selectin glycoprotein ligand 1 |
| 03/31/2005 | WO2004036221A3 Compositions and methods for diagnosing and treating autoimmune disease |
| 03/31/2005 | WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | US20050071894 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 03/31/2005 | US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents |
| 03/31/2005 | US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease |
| 03/31/2005 | US20050070706 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070694 Antagonistic anti-htnfsf13b human antibodies |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070670 Novel adjuvants and copolymer compositions |
| 03/31/2005 | US20050070610 Dermal compositions containing coenzyme q as the active ingredient |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders |
| 03/31/2005 | US20050070574 Novel compounds |
| 03/31/2005 | US20050070572 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070566 Imidazoquinoline derivatives |
| 03/31/2005 | US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions |
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070535 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder |
| 03/31/2005 | US20050070530 Dipeptidyl peptidase inhibitors |
| 03/31/2005 | US20050070529 Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| 03/31/2005 | US20050070525 Such as 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2- alpha ]benzimidazol-4(10H)-one |
| 03/31/2005 | US20050070514 Administering phosphodiesterase 4 inhibitor in combination with beta agonist and an anti-inflammatory steroid |
| 03/31/2005 | US20050070510 Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections |
| 03/31/2005 | US20050070491 Immunostimulatory nucleic acid molecules |
| 03/31/2005 | US20050070485 Phenylalanine derivatives |
| 03/31/2005 | US20050070464 Complex of sialic acid or a sialic acid derivative in an alpha 2-3 bond, galactose-monosaccharide, N-acetylated galactosamine-monosaccharide or glucosamine-monosaccharide, galactose- or glucose-monosaccharide; immunomodulation, immunosuppression and for treating infections in humans and animals |
| 03/31/2005 | US20050070463 membrane proteins associated with LPSs (lipopolysaccharides), for inducing maturation of dendritic cells; membrane fraction has a proteoglycan titer, represented by the sum of the contents of galactose and of proteins, between 1.2 g/l - 3.4 g/l for galactose and between 7.5 g/l - 14.9 g/l for proteins |
| 03/31/2005 | US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor |
| 03/31/2005 | US20050070005 High throughput or capillary-based screening for a bioactivity or biomolecule |
| 03/31/2005 | US20050069989 Isoflavone-beta-D-glucan produced by agaricus blazei in the submerged liquid culture and method of producing same |
| 03/31/2005 | US20050069983 Nucleotide sequences coding membrane protein for use in identifying modulator for prevention and treatment of herpes viral infection, cell proliferative and autoimmune disorders |
| 03/31/2005 | US20050069964 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC) |
| 03/31/2005 | US20050069943 101 human secreted proteins |
| 03/31/2005 | US20050069878 Proteins associated with cell growth, differentiation, and death |
| 03/31/2005 | US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069871 Polypeptide-human zinc finger protein fpm315-17 and the polynucleotide encoding it |
| 03/31/2005 | US20050069866 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 03/31/2005 | US20050069580 Compositions containing both sedative and non-sedative antihistamines and sleep aids |